- Home
- MOLN vs AMRN Comparison
MOLN vs AMRN Comparison
Compare MOLN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- AMRN
- Stock Information
- Founded
- MOLN 2004
- AMRN 1989
- Country
- MOLN Switzerland
- AMRN Ireland
- Employees
- MOLN N/A
- AMRN N/A
- Industry
- MOLN
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- AMRN Health Care
- Exchange
- MOLN Nasdaq
- AMRN Nasdaq
- Market Cap
- MOLN 195.4M
- AMRN 189.2M
- IPO Year
- MOLN 2021
- AMRN 1993
- Fundamental
- Price
- MOLN $5.56
- AMRN $0.56
- Analyst Decision
- MOLN
- AMRN Buy
- Analyst Count
- MOLN 0
- AMRN 1
- Target Price
- MOLN N/A
- AMRN N/A
- AVG Volume (30 Days)
- MOLN 7.1K
- AMRN 1.7M
- Earning Date
- MOLN 03-13-2025
- AMRN 02-27-2025
- Dividend Yield
- MOLN N/A
- AMRN N/A
- EPS Growth
- MOLN N/A
- AMRN N/A
- EPS
- MOLN N/A
- AMRN N/A
- Revenue
- MOLN $7,105,397.00
- AMRN $241,021,000.00
- Revenue This Year
- MOLN N/A
- AMRN N/A
- Revenue Next Year
- MOLN $29.41
- AMRN N/A
- P/E Ratio
- MOLN N/A
- AMRN N/A
- Revenue Growth
- MOLN N/A
- AMRN N/A
- 52 Week Low
- MOLN $3.32
- AMRN $0.43
- 52 Week High
- MOLN $12.70
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- MOLN 53.39
- AMRN 60.59
- Support Level
- MOLN $4.98
- AMRN $0.43
- Resistance Level
- MOLN $5.91
- AMRN $0.49
- Average True Range (ATR)
- MOLN 0.27
- AMRN 0.03
- MACD
- MOLN 0.08
- AMRN 0.01
- Stochastic Oscillator
- MOLN 69.45
- AMRN 91.43
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.